Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Shanthi Veerappapillai | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Shanthi Veerappapillai | Drug Discovery and Development | Best Researcher Award

Dr Shanthi Veerappapillai, Vellore Institute of Technology, India

Dr. Shanthi Veerappapillai is a distinguished Professor at VIT University, specializing in Bioinformatics and Computational Biology. With a Ph.D. from VIT, her research interests include computational protein analysis, drug resistance studies, and virtual screening, particularly focusing on infectious diseases like HIV and tuberculosis. She has led multiple funded research projects and published over 130 peer-reviewed articles. Dr. Veerappapillai has been recognized with awards like the Women Achiever Award for Sponsored Research Excellence (2020) and has supervised numerous Ph.D. graduates. Her dedication to education and research is also reflected in her active participation in conferences and professional societies. 👩‍🔬📚💻🌍

Publication Profile

Google Scholar

Education Qualification

Dr. Shanthi Veerappapillai holds a Ph.D. in Bioinformatics from VIT University, Tamil Nadu, India, and an M.Tech in Chemical Process and Design from SASTRA University, Tamil Nadu, India. She also earned a B.Tech in Chemical Engineering from EGS Pillai Engineering College, Bharathidasan University, Tamil Nadu, India. With a strong foundation in both chemical engineering and bioinformatics, Dr. Veerappapillai brings a multidisciplinary approach to her research and academic work. Her diverse academic background equips her with the expertise to bridge the gap between technology and biology, contributing to advancements in various scientific fields. 🧬⚙️🎓

Leadership in Research

Dr. Shanthi Veerappapillai is a dedicated scientist with extensive leadership experience as Principal Investigator (PI) in multiple prominent projects. Her research spans critical areas such as drug repurposing strategies and cancer research, showcasing her expertise in advancing both medical and computational biology. Through her work, she has contributed significantly to the development of innovative therapeutic approaches, emphasizing her commitment to enhancing healthcare and medical research. Her ability to lead and collaborate on large-scale projects underscores her impact in the field, making her a valuable asset in shaping the future of medical science and computational biology. 🧬🔬💊

Mentorship and Teaching

Dr. Shanthi Veerappapillai is a distinguished academic with vast experience in supervising successful Ph.D. candidates and teaching specialized subjects in biotechnology and bioinformatics. Her dedication to fostering academic development is evident in her role as a mentor to future researchers. With a passion for guiding students through advanced research topics, she has contributed significantly to shaping the next generation of experts in her field. Her work in biotechnology and bioinformatics continues to inspire students, encouraging innovation and critical thinking in these dynamic disciplines. 👩‍🔬📚🎓🔬👩‍💻

Community Engagement

Dr. Shanthi Veerappapillai is a dedicated academician who has made significant contributions to the scientific community through her active involvement in organizing conferences and workshops. As a member of various professional bodies, Dr. Veerappapillai continuously strengthens her presence in the academic world, sharing her expertise and collaborating with fellow researchers. Her commitment to advancing knowledge and fostering professional connections has had a lasting impact on her field. With a focus on promoting growth in the academic and scientific community, Dr. Veerappapillai’s efforts continue to inspire others. 🌍🧑‍🏫📚

Awards and Achievement

Dr. Shanthi Veerappapillai is a distinguished researcher with 131 peer-reviewed journal articles and an H-index of 14. She received the Best Chapter Award from BRSI-VIT for her exceptional contributions in 2023. She was honored with the Women Achiever Award for Sponsored Research Excellence in 2020 and has been a Research Fellow at INTI International University, Malaysia since June 2023. Dr. Veerappapillai’s academic journey includes producing 100% results in Chemical Engineering Thermodynamics courses and securing university ranks and prizes for academic excellence. She has also received several accolades, including a Best Poster Presentation Award at VIT University. 🏆📚👩‍🔬🌟

Research Focus

Dr. V. Shanthi’s research primarily focuses on molecular simulation, bioinformatics, and computational approaches to drug discovery. She has explored mechanisms of drug resistance, particularly in influenza virus neuraminidase, using molecular simulations to understand oseltamivir resistance. Her work also spans polypharmacology, investigating therapeutic agents for non-small cell lung cancer, and the identification of potential inhibitors for various viruses like H5N1. Additionally, she has contributed to bioprocess industry applications, drug repurposing, and plant-based therapeutic compounds. Her research aims at enhancing drug design, discovering novel therapeutic agents, and understanding the molecular interactions that govern drug efficacy. 🔬💊🦠💡

Publication Top Notes

Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach

Current progress and future perspectives of polypharmacology: From the view of non-small cell lung cancer

Bioactive Amento flavone isolated from Cassia fistula L. leaves exhibits therapeutic efficacy

Application of heat exchangers in bioprocess industry: a review

Multi-dimensional screening strategy for drug repurposing with statistical framework—a new road to influenza drug discovery

Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach

Role of the cation-π interaction in therapeutic proteins: A comparative study with conventional stabilizing forces

 

 

 

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Dr Ayaz Ahmed, ICCBS – University of Karachi, Pakistan

Dr. Ayaz Ahmed 🧬🔬 is a Principal Investigator and Assistant Professor at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), ICCBS, University of Karachi, Pakistan. With a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China, and an M.Sc. in Microbiology from the University of Karachi, his research focuses on microbial profiling, anti-biofilm agents, and infectious disease models. Dr. Ahmed has supervised numerous postgraduate students and received multiple international awards, including recognition from the American Society for Microbiology and Bill & Melinda Gates Foundation. He also leads funded projects on combating antibiotic-resistant pathogens. 🌟

Publication Profile

google scholar

Qualifications

Dr. Ayaz Ahmed holds a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China (2012), and a Master’s in Microbiology from the University of Karachi, Pakistan (2006, First Division). 🧬🎓 His doctoral research focused on the “Microbial profiling of dental plaque/Biofilm from dental caries and periodontitis patients” and explored the effects of Lactobacillus species on S. mutans biofilm formation. 🦷🔬 With a strong academic foundation and research expertise in microbiology and molecular biology, Dr. Ayaz contributes significantly to the understanding of microbial interactions in dental health and disease. 🌟

Job Responsibilities

Dr. Ayaz Ahmed is a Principal Investigator at the Cell Biology Lab, where he oversees the Imaging Facility, maintaining high-end fluorescence and light microscopes. He supports students by assisting them in acquiring high-quality images for their theses and manuscripts. Dr. Ahmed also manages the National Animal Facility for Laboratory Animal Research and Care. He supervises routine animal house operations and collaborates with a veterinary doctor to maintain SPF rats, mice, and hamsters. He is responsible for establishing models for infectious diseases and memory deficits to evaluate the efficacy of natural compounds. Dr. Ahmed also conducts toxicological studies and trains students in ethical animal research practices. 🧬🔬🐁

Student Supervised

Dr. Ayaz Ahmed and his team of dedicated researchers have made significant strides in their exploration of innovative therapeutic strategies. Among the Ph.D. candidates, Zulfiqar Ahmed’s research on controlling salmonellosis through probiotics in poultry, Binte Zehra’s study on modulating the metastatic potential of NSCLC, and Jazib Shafiq’s investigation into gut dysbiosis and anxiety have all been awarded. Additionally, Afshan Shams, Yamina Usmani, and Shariqa Khuwaja are examining the potential of natural and synthetic compounds in combating oral cancer and other diseases. Several M. Phil. students are also contributing to research on antimicrobial resistance and cancer therapies. 🧪🔬🧫

Honors and Awards

Dr. Ayaz Ahmed has earned numerous accolades throughout his distinguished career. In 2024, he received the Award for Collaborative Scientific Achievement from the Institute of Food Science and Technology, Chinese Academy of Agriculture Science, Beijing. He also became an International Federation for Biosafety Association (IFBA) Certified Biological Waste Management Professional and Bio-risk Management Professional in 2023. Dr. Ahmed was selected as a Mentor for the ASM Future Leaders Mentoring Fellowship Program in 2023 and was awarded the Health Security Partner Grant by the Bill & Melinda Gates Foundation in 2021. He has also earned prestigious travel awards and fellowships, including the American Society for Microbiology ID Fellowship and the Science and Technology Talent Award. 🏅🌍🦠

Completed Projects

Dr. Ayaz Ahmed has led multiple impactful research projects focused on combating multidrug-resistant microorganisms and improving public health. His research on the effect of synthetic and natural compounds on biofilm formation was funded by the Higher Education Commission of Pakistan (HEC) under project # HEC No: PD-IPFP/HRD/HEC/ 2013/1182. He also contributed to projects such as Personal Protective Equipment for Sindh Poultry Vaccine Center (funded by CRDF Global, USA), and oral pathogens related to dental caries (funded by ICCBS). Notably, his work on antimicrobial-resistant water contaminants, funded by the U.S.-Pakistan Centers for Advanced Studies in Water, aims to improve water quality. He further advanced research on antimicrobial and antibiofilm agents targeting Acinetobacter baumannii and Klebsiella pneumonia with funding from HEC. 💧🔬🦠

Professional Experience

Dr. Ayaz Ahmed has had a distinguished career in academia and research. Since June 2017, he has been serving as an Assistant Professor at the International Center for Chemical and Biological Sciences, University of Karachi. Prior to this, he worked as a Senior Research Officer at the same institution from November 2013 to June 2017. Dr. Ahmed also pursued Post-Doctoral training in Behavioral Sciences at Hunan Drug Safety Evaluation in Changsha, China, from January 2016 to February 2017. His earlier roles include Assistant Professor on Interim Placement, Research Officer in Avian Influenza Vaccine Production, and a research intern in the National Internship Program. 🧪📚

Professional Membership

Dr. Ayaz Ahmed is an active member of several prestigious professional organizations, contributing significantly to the fields of microbiology and infectious diseases. His memberships include the American Society for Microbiology (ASM) 🦠, the Pakistan Biological Safety Association (PBSA) 🧫, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 🌍. Additionally, he is a member of the American Association of Cancer Research (AACR) 🎗️ and the Medical Microbiology & Infectious Disease Society of Pakistan (MMIDSP) 🇵🇰. These memberships reflect his commitment to advancing research and innovation in microbiology, infectious diseases, and cancer research.

Research Focus

Dr. Ayaz Ayaz Ahmed research focus primarily revolves around microbiology, particularly in the fields of gut microbiota analysis, antimicrobial resistance, and biofilm formation. His studies often investigate the interactions between microorganisms and the human or animal host, such as comparing gut microbe profiles between healthy individuals and those with conditions like hyperthyroidism and liver cirrhosis. Additionally, Dr. Ahmed explores innovative therapeutic approaches, including the development of antimicrobial agents, such as nanoparticles conjugated with antibiotics to combat biofilm-forming pathogens like Klebsiella pneumoniae and Staphylococcus aureus. His work has significant implications for medical microbiology and the treatment of infectious diseases. 🦠🔬

Publication Top Notes

Gut microbe analysis between hyperthyroid and healthy individuals

Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan

Biofilm inhibitory effect of chlorhexidine conjugated gold nanoparticles against Klebsiella pneumoniae

Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals

Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae

Effect of Lactobacillus species on Streptococcus mutans biofilm formation.

Comparison of oral microbiota in orthodontic patients and healthy individuals

Synthesis and Chemosensing of Nitrofurazone using Olive oil based Silver Nanoparticles (O-AgNPs)

Isolation of dihydrobenzofuran derivatives from ethnomedicinal species Polygonum barbatum as anticancer compounds

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Prof.Mohamed Abdel-Aziz, Drug Discovery and Development,Best Researcher Award-1133

Published on by Top Pharmaceutical

Prof.Mohamed Abdel-Aziz, Drug Discovery and Development ,Best Researcher Award

Prof.Mohamed Abdel-Aziz, at National Research Centre,Egypt

Author Profile

🎓 Education:

He earned his PhD in Microbiology from Ain Shams University, specializing in Physiological and Genetical Studies on Dextranase Formation by Fungi. His academic journey includes a Master’s degree from Mansoura University and a Bachelor’s degree in Botany.

🔍 Research Focus:

Dr. Abdel-Aziz’s research primarily focuses on Microbial Chemistry, with extensive contributions to understanding microbial enzymes and bioactive compounds.

🌐 International Collaborations:

He has participated in several scientific missions and collaborations worldwide, including Italy, Great Britain, China, Germany, and Sweden, enriching his research with diverse perspectives.

📘 Publications:

Dr. Abdel-Aziz has authored over 145 publications, including original articles, reviews, and books, notably contributing to advancements in microbiology and biotechnology.

🏆 Achievements:

He holds seven patents and has been involved in numerous national and international research projects, enhancing the field’s knowledge and applications.

🌟 Recognition:

With an h-index of 31 and over 3000 citations, his work continues to influence the scientific community globally.

🎓Publication Top Noted:

Paper Title : Effect of plasma superficial treatments on antibacterial functionalization and coloration of cellulosic fabrics

  • Authors: Eid B. M. and Abdel-Aziz M. S. Ibrahim N. A.
  • Journal: Applied Surface Science
  • Year: 2017
Paper Title :Preparation of polystyrene nanocomposites based on silver nanoparticles using marine bacterium for packaging
    • Authors: Ahmed M Youssef, Mohamed S Abdel-Aziz
    • Journal:Polymer-Plastics Technology and Engineering
    • Year: 2013
Paper Title : Seven naphtho-γ-pyrones from the marine-derived fungus Alternaria alternata: structure elucidation and biological properties
  • Authors: Mohamed Shaaban, Khaled A Shaaban, Mohamed S Abdel-Aziz
  • Journal:Organic and medicinal chemistry letters
  • Year: 2012
Paper Title :Seven naphtho-γ-pyrones from the marine-derived fungus Alternaria alternata: structure elucidation and biological properties
  • Authors: Mohamed Shaaban, Khaled A Shaaban, Mohamed S Abdel-Aziz
  • Journal:Organic and medicinal chemistry letters
  • Year: 2012

Paper Title :Design, synthesis and biological investigation of certain pyrazole-3-carboxylic acid derivatives as novel carriers for nitric oxide

  • Authors: El-Shimaa MN Abdel-Hafez, Gamal El-Din AA Abuo-Rahma, Mohamed Abdel-Aziz, Mohamed F Radwan, Hassan H Farag
  • Journal:Bioorganic & medicinal chemistry
  • Year: 2009